PT-141
Sourcing GuideQuality control discipline for PT-141 extends across procurement, storage, reconstitution, and use. Lyophilised vial inspection, COA cross-reference against lot, 1025 Da mass spec confirmation, and HPLC purity above 98% are the procurement layer; the storage and reconstitution layer is examined below.
Key Takeaways
Procurement lens: PT-141 sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching 1025 Da. Mechanism: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days. Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger). Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.
Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Effect is centrally mediated (unlike PDE5 inhibitors which act peripherally on vascular smooth muscle). Cross-reactivity with MC3R/MC5R contributes to nausea and flushing side effects. Sourcing implications: the mechanism dictates which analytical assays are appropriate for QC, which storage conditions preserve activity, and which reconstitution and use practices matter. The subsections below cover HPLC and analytical identity, COA evaluation and red flags, reconstitution and storage, and vendor tier comparison for PT-141.
HPLC purity and analytical identity
Minimum acceptable HPLC purity for PT-141 is ≥98% in research-grade material. Mass spec confirmation should show the characteristic m/z of 1025 (M+H)+. Contaminant peaks above 1% in the HPLC trace warrant quantification on the COA and — ideally — structural identification of the major impurities.
Vendor tier comparison and price discipline
Three vendor tiers operate in the PT-141 market: pharmaceutical-grade compounded prescription (physician-supervised, full COA, ICP-MS where relevant, highest cost), reputable research-chemical vendors (full COA, lot-specific, mid-tier cost), and grey-market unverified sources (template or absent COA, unverifiable supply chain, lowest cost). The price differential between tiers is roughly 3–5x; the quality differential is substantially larger and concentrated in the bottom tier.
Reconstitution and storage protocols
PT-141 is typically supplied lyophilised in glass vials for reconstitution with bacteriostatic water. Standard reconstitution: dissolve at 1–2 mg/mL, store reconstituted material at 4°C, and use within 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Lyophilised storage at −20°C extends shelf life to 18–24 months for most peptides in this class.
For users targeting pricing analysis, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.
Sourcing PT-141 for bac water sourcing use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.
Pharmaceutical-grade compounded PT-141 is the lowest-risk sourcing path for gmp vs research grade use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.
For users targeting cold chain, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 1.75 mg (approved) | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1.75 mg (approved) | 4–6 weeks initial cycle |
| Sourcing Guide focus | SubQ | 1.75 mg (approved) | PRN, max 1x in 24 hr, 8x monthly |
| Maintenance phase | SubQ | 1.75 mg (approved) | Ongoing with periodic pauses |
Dose timing for PT-141 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
PT-141 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.
- PT-141 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with PT-141's mechanism in sourcing / quality / procurement protocols.
- PT-141 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with PT-141's mechanism in sourcing / quality / procurement protocols.
- PT-141 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with PT-141's mechanism in sourcing / quality / procurement protocols.
- PT-141 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with PT-141's mechanism in sourcing / quality / procurement protocols.
Nausea most common. Transient BP elevation. Hyperpigmentation with chronic use. Avoid in uncontrolled hypertension or CVD history.
Lens-specific safety considerations for sourcing / quality / procurement use of PT-141: Nausea most common. Transient BP elevation. Hyperpigmentation with chronic use. Avoid in uncontrolled hypertension or CVD history. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | Sourcing Guide |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
Lot variability across orders?
Pharmaceutical-grade versus research-grade?
Visual quality inspection?
Storage protocol?
How long until I see results from PT-141?
What is the evidence base for PT-141?
Start a PT-141 Protocol
Alukard provides GMP-certified physician-supervised sourcing with GMP-certified PT-141 and Pharmaceutical-grade compounds with full COA documentation.
Get ProtocolQuick Facts
- Molecular weight
- 1025 Da
- Sequence length
- 7 aa
- Half-life
- ~2-3 hr
- WADA
- Not on prohibited list
- FDA
- Approved (Vyleesi 2019)
- Research
- Phase III
Stack Partners
All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for PT-141 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Sourcing / Quality / Procurement Protocol for PT-141
Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.
HIPAA Compliant · GMP Certified · Physician Supervised